HomeAI · summaries
Storia in 4 fonti
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics - Lantheus Holdings (NASDAQ:LNTH)
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Tauklarify for PET imaging of tau neurofibrillary tangle pathology
The FDA has approved Tauklarify as a radiodiagnostic agent for adults with cognitive impairment being evaluated via PET scan to identify tau neurofibrillary tangle pathology…
- ·
morningstar.com
Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for…
Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease
